Tirzepatide microdosing in multi-dose pens reveals significant evidence gaps in safety and efficacy for clinical individualization.
Microdosing Tirzepatide in Multi-Dose Pens: Clinical Individualization, Safety, and Evidence Gaps.
Background
Obesity management often involves GLP-1/GIP receptor co-agonists like tirzepatide, which demonstrate significant weight loss and glycemic control. However, factors such as cost, side effect management, or perceived individual needs have led to off-label practices like microdosing using multi-dose pens. This creates a critical gap in understanding the actual safety, efficacy, and optimal clinical application of such individualized, non-standardized regimens, necessitating a comprehensive review of current evidence and practice considerations.